FDA Advisory Committee Votes to Keep Avandia on the Market

FDA's joint advisory committee voted (22-1) to keep GlaxoSmithKline's diabetes drug Avandia on the market with a black box warning for patients at higher cardiovascular risk. All the votes came with the caveat for stronger warnings.

But they voted 20-3 that Avandia increases the cardiac ischemic risk in type 2 diabetes. What an odd vote.

We don't think it means very much and that Avandia, for all intents and purposes, is dead. See our previous post below. What do you all think?